The accompanying table (click to enlarge) includes an updated calendar of 78 expected FDA new product decisions with more detailed comments for each entry. Click here for a link to my previous FDA calendars and the list below highlights companies with pending decisions + market caps below $100M, making them ideal candidates for extreme trading opportunities. <a[More...]

This morning, Nuvelo announced positive results from the Phase 1 trial of recombinant, secreted protein, NU206, the company’s lead compound from its Wnt Therapeutics Program. The single-center, double-blind, placebo-controlled, single-ascending dose (SAD) trial involved 32 healthy male volunteers. According to the press release, NU206 caused no serious adverse side effects and pharmacokinetics were predictable. Dr. Ted W. Love, chairman and CEO of Nuvelo, stated, “Based on preclinical studies, we believe that NU206 promotes cell growth and repair, and, based also on results from this Phase 1 trial, believe it has the potential to offer a novel approach for the treatment of serious medical conditions such as gastrointestinal (GI) injury, inflammatory bowel disease, and bone disease.” He added, “Because Nuvelo is in the process of merging with ARCA biopharma to create a cardiovascular-focused company, we are currently evaluating[More...]

China Unicom (CHU) announced it was merging with China Netcom (CN) and selling its CDMA business to China Telecom (CHA). The new China Unicom will become a full telecom service operator after the deal and won't operate two wireless networks at the same time. However, China Unicom will have difficulty integrating China Netcom's fixed-line telecom business.... [More...]